Uncover key drivers, emerging technologies, and competitive movements shaping the respiratory disease vaccine market from 2025–2034 with trusted insights from The Business Research Company
How Is The Respiratory Disease Vaccine Market Size Expected To Expand Over 2029-2034?
The market for respiratory disease vaccines has shown slight expansion over the past few years. This market is projected to expand from $69.99 billion in 2024 to $70.03 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 0.1%. Historically, this expansion has been driven by factors such as the increasing incidence of respiratory ailments, heightened public understanding of vaccination, various public health programs, and a rising need for vaccines that are both effective and better tolerated.
The respiratory disease vaccine market size is projected to experience consistent expansion over the upcoming years. It is anticipated to grow to $77.48 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 2.6%. The expansion during the forecast period is driven by an aging population, rising healthcare spending, investments in vaccine, and pandemic preparedness initiatives. Notable trends for this period include innovative vaccines, collaborative research, advancements in vaccine development, and refined drug approval processes.
Access A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp
Which Market Factors Are Fueling The Respiratory Disease Vaccine Industry Growth?
The anticipated rise in tuberculosis cases is projected to fuel the expansion of the respiratory disease vaccine market. Tuberculosis (TB), a respiratory illness, originates from the bacterium Mycobacterium tuberculosis, primarily targeting the lungs but capable of affecting other bodily organs and systems, resulting in diverse complications. A growing occurrence of tuberculosis could accelerate initiatives to create and distribute respiratory disease vaccines, thereby curbing its transmission. As an illustration, in November 2023, data from the Centers for Disease Control and Prevention, a US-based Government agency, indicated that the United States recorded 8,331 tuberculosis (TB) cases in 2022, representing a 5.9% rise in the number of cases compared to 2021. The incidence rate climbed to 2.5 cases per 100,000 people, showing a 5.5% increase over the preceding year. Consequently, the rising prevalence of tuberculosis will stimulate the respiratory disease vaccine market.
Which Categories Are Covered In The Respiratory Disease Vaccine Market Segmentation Analysis?
The respiratory disease vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users
Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV
Which Market Trends Are Expected To Define The Future Of The Respiratory Disease Vaccine Market?
Leading firms in the respiratory disease vaccine market are prioritizing the development of novel products to boost their effectiveness and offer enhanced options for preventing and treating respiratory disease infections. An illustration of this trend is Pfizer Inc., a pharmaceutical company based in the US, which in May 2023 secured Food and Drug Administration (FDA) approval for its bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine). This approval was specifically for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is an unadjuvanted vaccine, composed of a pair of preF proteins designed to maximize immunity against RSV A and B varieties, and has demonstrated clinical safety and productivity.
Which Organizations Are At The Forefront Of The Respiratory Disease Vaccine Market?
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
Download The Full Report Here:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report
Which Geographic Areas Are Driving Strong Demand For The Respiratory Disease Vaccine Market?
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get A Report Customized For You Here:
https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp
Browse Through More Reports Similar to the Global Respiratory Disease Vaccine Market 2025, By The Business Research Company
Respiratory Devices And Equipment Therapeutic And Diagnostic Global Market Report 2025
Respiratory Disposables Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report
Respiratory Devices And Equipment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model